The evidence layer
GLP-1 Research: Trials, Mechanisms, and the Pipeline
Every science explainer on the site, ordered — from receptor mechanisms to SURMOUNT-5's head-to-head to the triple agonist posting 24% in phase 2.
Mechanisms
How tirzepatide works (GIP + GLP-1) · How semaglutide works (GLP-1)
The trials
SURMOUNT-1 through -5, explained · STEP & SELECT, explained · Tirzepatide vs semaglutide head-to-head
Applied science
Muscle loss & lean-mass protection · Plateaus: physiology & next moves · Stopping & weight regain (SURMOUNT-4) · Oral semaglutide (OASIS)
Pipeline & new approvals
Foundayo (orforglipron): approved April 2026 · Retatrutide phase 3: 28.7–30.3% · Full pipeline map
Editorial standard for all of it: primary trial publications and FDA materials first, effect sizes with their populations attached, and no borrowed evidence — compounded products get the approved products' trial numbers as context, never as claims. Details: editorial policy · sources.